NASDAQ:ETTX Entasis Therapeutics (ETTX) Stock Price, News & Analysis → The Next Step of Their Control Is Here … (From Weiss Ratings) (Ad) Free ETTX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$2.19▼$2.1950-Day Range$2.18▼$2.2052-Week Range$1.40▼$3.88Volume800 shsAverage Volume239,104 shsMarket Capitalization$104.80 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Entasis Therapeutics alerts: Email Address Ad Weiss RatingsThe Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.4 simple steps to protect your privacy and money before it’s too late. About Entasis Therapeutics Stock (NASDAQ:ETTX)Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate zoliflodacin. Entasis Therapeutics Holdings Inc. was founded in 2015 and is headquartered in Waltham, Massachusetts. Entasis Therapeutics Holdings Inc. operates as a subsidiary of Innoviva, Inc.Read More Ad Weiss RatingsThe Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.4 simple steps to protect your privacy and money before it’s too late. ETTX Stock News HeadlinesJuly 18, 2022 | insidermonkey.comHedge Fund and Insider Trading News: D.E. Shaw, Elliott Management, Millennium Management, Marshall Wace LLP, Three Arrows Capital, Entasis Therapeutics Holdings Inc. (ETTX), Gossamer Bio Inc (GOSS), and MoreJune 9, 2022 | finance.yahoo.comEntasis Therapeutics Presents Data on Sulbactam-Durlobactam and ETX0462 at 2022 ASM Microbe Annual ConferenceApril 26, 2024 | Weiss Ratings (Ad)The Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.June 9, 2022 | finance.yahoo.comEntasis Therapeutics Presents Data on Sulbactam-Durlobactam and ETX0462 at 2022 ASM Microbe Annual ConferenceJune 9, 2022 | apnews.comINVESTIGATION ALERT: Halper Sadeh LLP Investigates MANT, ETTX, CTEKJune 3, 2022 | apnews.comScott+Scott Attorneys at Law LLP Investigates Innoviva Buyout of Entasis – ETTXMay 31, 2022 | apnews.comSHAREHOLDER NOTICE: Halper Sadeh LLP Investigates ETTX, CDEV, CTEKMay 25, 2022 | finance.yahoo.comBiotech Stock Roundup: ETTX Up on Acquisition Deal, REGN Offers UpdatesApril 26, 2024 | Weiss Ratings (Ad)The Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.May 25, 2022 | apnews.comENTASIS ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of ETTX and Encourages Investors to Contact the FirmMay 24, 2022 | apnews.comSHAREHOLDER ALERT: Halper Sadeh LLP Investigates ETTX, CTEK, VSAT, WLL, LHCGMay 24, 2022 | finance.yahoo.comAstraZeneca spinout, based in Waltham, acquired at 60% premiumMay 24, 2022 | benzinga.comInvestor Alert - The M&A Class Action Firm Announces an Investigation of Entasis Therapeutics Holdings Inc. - ETTXMay 23, 2022 | apnews.comETTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Entasis Therapeutics Holdings Inc. Is Fair to ShareholdersMay 19, 2022 | finance.yahoo.comAntibiotic resistance efforts get a boost as CARB-X gets $370MMay 17, 2022 | finance.yahoo.comEntasis Therapeutics Presents Data Highlights from Phase 3 ATTACK Trial at 2022 American Thoracic Society Annual ConferenceMay 17, 2022 | finance.yahoo.comEntasis Therapeutics Presents Data Highlights from Phase 3 ATTACK Trial at 2022 American Thoracic Society Annual ConferenceApril 27, 2022 | finance.yahoo.comEntasis Therapeutics Announces First Quarter 2022 Financial Results and Provides Business UpdateApril 27, 2022 | finance.yahoo.comEntasis Therapeutics Announces First Quarter 2022 Financial Results and Provides Business UpdateApril 26, 2022 | finance.yahoo.comEntasis Therapeutics Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at ECCMID 2022 ConferenceApril 18, 2022 | baystreet.caEntasis Flat on DataApril 18, 2022 | finance.yahoo.comEntasis Therapeutics Presents SUL-DUR Topline Data from Phase 3 ATTACK Trial at ECCMID 2022 ConferenceMarch 16, 2022 | benzinga.comAlliance Global Partners Downgrades Entasis Therapeutics Hldg to NeutralMarch 15, 2022 | marketwatch.comEntasis Shares Rise After Innoviva Raises Buyout Price to $2 a ShareMarch 8, 2022 | benzinga.comWedbush Downgrades Entasis Therapeutics Hldg to Neutral, Lowers Price Target to $1.8March 4, 2022 | benzinga.comHC Wainwright & Co. Downgrades Entasis Therapeutics Hldg to Neutral, Lowers Price Target to $1.8March 3, 2022 | finance.yahoo.comEntasis Therapeutics Announces Year End 2021 Financial Results and Provides Business UpdateSee More Headlines Receive ETTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Entasis Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today4/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:ETTX CUSIPN/A CIK1724344 Webwww.entasistx.com Phone(781) 810-0120FaxN/AEmployees51Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-47,140,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-145.48% Return on Assets-103.75% Debt Debt-to-Equity RatioN/A Current Ratio1.65 Quick Ratio1.65 Sales & Book Value Annual Sales$7 million Price / Sales14.97 Cash FlowN/A Price / Cash FlowN/A Book Value$0.66 per share Price / Book3.32Miscellaneous Outstanding Shares47,852,000Free Float44,742,000Market Cap$104.80 million OptionableNot Optionable Beta1.33 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. Manoussos Perros Ph.D. (Age 54)Pres, CEO & Director Comp: $1.09MDr. Ruben Tommasi (Age 56)Chief Scientific Officer Comp: $704.98kDr. David Altarac M.D. (Age 61)MPA, Chief Medical Officer Comp: $801.88kMs. Kristie Wagner (Age 55)Interim VP and Interim Principal Financial & Accounting Officer Ms. Elizabeth M. Keiley (Age 56)Gen. Counsel Dr. John Patrick Mueller Ph.D. (Age 62)Chief Devel. Officer Dr. Matthew Ronsheim Ph.D. (Age 50)Chief Pharmaceutical Sciences & Manufacturing Officer Ms. Anna Diaz Triola MBA (Age 47)Chief Commercial Officer More ExecutivesKey CompetitorsEliem TherapeuticsNASDAQ:ELYMFibroGenNASDAQ:FGENClearside BiomedicalNASDAQ:CLSDCyteir TherapeuticsNASDAQ:CYTTBarinthus BiotherapeuticsNASDAQ:BRNSView All Competitors ETTX Stock Analysis - Frequently Asked Questions How were Entasis Therapeutics' earnings last quarter? Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) issued its earnings results on Thursday, November, 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.26). During the same period in the prior year, the company posted ($0.37) EPS. What other stocks do shareholders of Entasis Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Entasis Therapeutics investors own include VBI Vaccines (VBIV), Dynavax Technologies (DVAX), Evofem Biosciences (EVFM), Fulcrum Therapeutics (FULC), Matinas BioPharma (MTNB), SCYNEXIS (SCYX), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX) and Viking Therapeutics (VKTX). When did Entasis Therapeutics IPO? Entasis Therapeutics (ETTX) raised $75 million in an initial public offering (IPO) on Wednesday, September 26th 2018. The company issued 4,400,000 shares at $16.00-$18.00 per share. Credit Suisse and BMO Capital Markets acted as the underwriters for the IPO and SunTrust Robinson Humphrey and Wedbush PacGrow were co-managers. This page (NASDAQ:ETTX) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchJeff Bezos Just Humiliated Elon MuskInvestorPlaceEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entasis Therapeutics Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
